Avesi Partners ("Avesi") announced that it has made an investment in Visante (or the "Company"), a leading provider of specialized tech-enabled consulting and advanced partnership services focused on helping health systems accelerate financial and operational performance through their pharmacy offerings. Avesi has partnered alongside the existing management team to support Visante's overall mission of positively transforming healthcare through pharmacy, with a specific emphasis on the specialty and infusion pharmacy markets.

In the first 10 months of 2023, 1,268 Wegovy prescriptions were written for adolescents with obesity — a more than 50-fold increase from 2022, according to an exclusive Reuters report. 

A COVID-19 antiviral therapy authorized in Japan, ensitrelvir, shortened the duration of symptoms from five days to four days in a phase 3 study.

Senators are urging the FDA to update decade-old guidance and take action to rein in social media advertisements of prescription drugs from telehealth companies, requesting that the agency respond to their concerns by March 27, according to a Feb. 15 Wall Street Journal report. 

The Federal Trade Commission and HHS launched an investigation Feb. 14 into how group purchasing organizations and drug wholesalers might cause drug shortages. 

Mark Cuban Cost Plus Drug Co. now offers critical drugs in shortage to healthcare providers. 

Harvard University researchers have received $1.2 million from CARB-X, a Boston University-led nonprofit that funds projects that focus on drug-resistant bacteria named on the CDC’s Antibiotic Resistant Threats list.

The FDA has sent warning letters to two online vendors — US Chem Labs and Helix Chemical Supply — for selling unapproved and misbranded versions of semaglutide and tirzepatide.

On Feb. 14, the FDA approved Aurlumyn, the nation's first treatment for severe frostbite. 

After GSK discontinued its brand-name asthma drug Flovent on Jan. 1, families and physicians are struggling to access its generic solution, CNN reported Feb. 13. 

Healthcare suppliers and food companies are veering into new business plans amid the booming market for weight loss medications, which is expected to reach $80 billion by 2030.

The FDA has granted approval to a new medicine for patients with aggressive, metastatic pancreatic adenocarcinoma. The agency began its priority review of the drug following positive phase 3 trial results.

Gilead Sciences bought a liver disease drugmaker Feb. 12 for $4.3 billion. 

Ervebo, Merck's Ebola vaccine, reduced the fatality risk among patients who previously contracted the rare disease that kills 50% of those affected, according to new research. 

Dallas-based UT Southwestern Medical Center is partnering with Pfizer to develop RNA-enhanced delivery technologies for genetic medicine therapies.

More than 2 million 2,363,168 products BD Sensi-Disc products cannot be used for Haemophilus influenzae testing, a Becton Dickinson spokesperson told Becker's.

The University of Michigan in Ann Arbor has piloted a program aimed at involving pharmacists as part of the care team for patients with hypertension. Its success has prompted the CDC to begin scaling the model for wider use.

A chemotherapy drug could potentially be a treatment for Parkinson's disease, a recent study found.

A growing number of companies ranging from gyms to meal delivery services are launching new offerings to capitalize on a known issue that can happen for patients on weight loss drugs such as Ozempic and Wegovy, The New York Times reported Feb. 8. 

Ohio's Board of Pharmacy handed a CVS pharmacy a $250,000 fine and probation for at least three years following a 2021 investigation that found understaffing, a broken air conditioning unit, unsafe storage for medications and other issues.